Associated Papers
Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma.
Pitiyarachchi O et al.
Translational Oncology, 2023
36805919 (PubMed )
Supplement: mmc1.docx
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
Garcia-Prieto CA et al.
Bioinformatics (oxford, England), 2022
35512388 (PubMed )
Supplement: btac306_supplementary_data.zip › Supplementary_files.zip › Supplementary_files › Supplementary_file_7.xlsx › Sheet1
Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency.
Bajrami I et al.
Communications Biology, 2021
34750509 (PubMed )
Supplement: 42003_2021_2770_MOESM9_ESM.xlsx › Fig_S13
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes.
Riaz N et al.
Nature Communications, 2017
29021619 (PubMed )
Supplement: 41467_2017_921_MOESM5_ESM.xlsx › Sheet1
Association between targeted somatic mutation (TSM) signatures and HGS-OvCa progression.
Lindley RA et al.
Cancer Medicine, 2016
27485054 (PubMed )
Supplement: CAM4-5-2629-s002.pdf
Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations.
Martelotto LG et al.
Genome Biology, 2014
25348012 (PubMed )
Supplement: 13059_2014_484_MOESM2_ESM.xlsx › Additional_file_2
Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.
Liu G et al.
Pharmacogenomics, 2012
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Yang D et al.
Jama, 2011
Integrated genomic analyses of ovarian carcinoma.
Unknown Author
Nature, 2011
21720365 (PubMed )
Supplement: NIHMS313090-supplement-8.pdf
Select a paper to view details